Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd. announced formal results of a comparative study to investigate aortic flow physiology by cardiac MRI (cMRI) in five patients who received a DurAVR transcatheter aortic valve (first- in-human). The study compared DurAVR to normal age-height-weight matched controls, other transcatheter aortic valve implants (TAVI) and patients who had surgical aortic valve replacement (SAVR). "DurAVR TAVI novel leaflet design restores ascending aortic flow haemodynamics on cardiac MRI" was presented at the annual PCR London Valves 2022 Congress, 27-29 November 2022.

Dr. Pankaj Garg, Associate Professor in Cardiology, at the University of East Anglia and Consultant Cardiologist at Norfolk and Norwich University Hospital quantified key heart valve performance parameters in the ascending aorta using phase-contrast (PC) MRI (a noninvasive method for imaging blood and tissue velocity). These included aortic forward flow (AFF), aortic regurgitation (AR), aortic flow displacement (AFD) at peak systole and aortic flow reversal (AFR) at peak systole. Study results demonstrated the novel leaflet design of DurAVRTM THV restored ascending aortic flow haemodynamics, whereas SAVR and other TAVI valves did not demonstrate the same physiological advantage.